



Published in final edited form as:

*J Allergy Clin Immunol.* 2019 May ; 143(5): 1865–1877.e4. doi:10.1016/j.jaci.2018.08.053.

## Mast Cell CRF<sub>2</sub> Suppresses Mast Cell Degranulation and Limits the Severity of Anaphylaxis and Stress-Induced Intestinal Permeability

Susan D'Costa, PhD<sup>3</sup>, Saravanan Ayyadurai, PhD<sup>1</sup>, Amelia J. Gibson, PhD<sup>4</sup>, Emily Mackey<sup>1,5</sup>, Mrigendra Rajput<sup>1</sup>, Laura J. Sommerville<sup>6</sup>, Neco Wilson<sup>1</sup>, Yihang Li, PhD<sup>1</sup>, Eric Kubat, MD<sup>8</sup>, Ananth Kumar, PhD<sup>2</sup>, Hariharan Subramanian<sup>2</sup>, Aditi Bhargava, PhD<sup>7</sup>, Adam J. Moeser, DVM PhD<sup>1,2,\*</sup>

<sup>1</sup>Gastrointestinal Stress Biology Laboratory, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA

<sup>2</sup>Department of Physiology, Michigan State University

<sup>3</sup>Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599

<sup>4</sup>KeraFast, Boston, MA

<sup>5</sup>Comparative Biomedical Sciences Program, North Carolina State University, Raleigh, NC 27606

<sup>6</sup>Department of Pathology, Duke University, School of Medicine.

<sup>7</sup>Department of Surgery, University of California, San Francisco; The Osher Center for Integrative Medicine, University of California, San Francisco.

<sup>8</sup>Department of Surgery, East Bay, University of California, San Francisco

### Abstract

**Background:** Psychological stress and heightened MC activation are linked with important Immunological disorders including allergy, anaphylaxis, asthma, and functional bowel diseases, but the mechanisms remain poorly defined. We have previously demonstrated that activation of the corticotropin releasing factor (CRF) system potentiates MC degranulation responses during IgE-mediated anaphylaxis and psychological stress, via CRF receptor subtype 1 (CRF<sub>1</sub>) expressed on MCs.

**Objective:** In this study, we investigated the role of CRF receptor subtype 2 (CRF<sub>2</sub>) as a modulator of stress-induced MC degranulation and associated disease pathophysiology.

\*Correspondence and requests for materials should be addressed to: Adam J. Moeser, DVM, Ph.D., Gastrointestinal Stress Biology Laboratory, Department of Large Animal Clinical Sciences, Neuroscience Program, Physiology, Michigan State University, East Lansing, MI 48824, Phone: 517-353-5978; Fax: 517-432-1042; moeserad@cvm.msu.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Disclosure:

The authors declare no conflict of interest.


**Methods:** *In vitro* MC degranulation assays were performed with bone marrow derived MCs (BMMCs) derived from WT and CRF<sub>2</sub>-deficient (CRF<sub>2</sub><sup>-/-</sup>) mice and RBL-2H3 MCs transfected with CRF<sub>2</sub>-overexpressing plasmid or CRF<sub>2</sub>-siRNA. *In vivo* MC responses and associated pathophysiology in IgE-mediated passive systemic anaphylaxis (PSA) and acute psychological restraint stress were measured in WT, CRF<sub>2</sub><sup>-/-</sup>, and MC-deficient *Kit*<sup>W-sh/W-sh</sup> knock-in mice.

**Results:** Compared with WT mice, CRF<sub>2</sub><sup>-/-</sup> exhibited heightened serum histamine levels and exacerbated PSA-induced anaphylactic responses and colonic permeability. In addition, CRF<sub>2</sub><sup>-/-</sup> mice exhibited increased serum histamine and colonic permeability following acute restraint stress. Experiments with BMMCs and RBL-2H3 MCs demonstrated that CRF<sub>2</sub> expressed on MCs suppresses store-operated Ca<sup>2+</sup> entry (SOCE) signaling and MC degranulation induced by diverse MC stimuli. Experiments with MC-deficient *Kit*<sup>W-sh/W-sh</sup> mice systemically engrafted with WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs demonstrated the functional importance of MC-CRF<sub>2</sub> in modulating stress-induced pathophysiology.

**Conclusions:** MC CRF<sub>2</sub> is a negative, global modulator of stimuli-induced MC degranulation and limits the severity of IgE-mediated anaphylaxis and stress-related disease pathogenesis.

## Graphical Abstract

### CRF<sub>2</sub> is a Global Negative Modulator of Stimuli-Induced Mast Cell Degranulation



SOCE: store-operated Ca<sup>2+</sup>-entry; CRF<sub>1</sub>: Corticotropin releasing factor receptor subtype 1; CRF<sub>2</sub>: Corticotropin releasing factor receptor subtype 2; Ucn: Urocortin; STIM1: Stromal interaction molecule 1; Orai1: ORAI calcium release-activated calcium modulator 1; TRPC: transient receptor potential cation channels

## Capsule summary:

Targeting CRF<sub>2</sub> and (or) downstream pathways has potential as a new therapeutic approach to limit excessive MC activation and intestinal permeability which initiate and perpetuate highly prevalent and burdensome diseases including allergy, anaphylaxis and functional bowel disorders.

## Keywords

Mast cell; corticotropin releasing factor receptor; stress; anaphylaxis; allergy; intestinal permeability

---

## Introduction

Psychological stress has a major influence on immune function and is a risk factor in many immune-related disorders. While numerous studies have investigated the influence of different stress paradigms on immune function and disease susceptibility, the underlying signaling pathways remain to be elucidated. Mast cells have become recognized as important early immune effectors cells in the stress response and stress-related pathophysiology. Mast cells are strategically positioned close to neurovascular units and host-environmental interfaces (e.g. mucosal epithelial barriers) and express a repertoire of receptors to sense and respond rapidly to a continuous array of stress signals from neuroendocrine, immunological and environmental origins. Upon activation, MCs release an array of preformed granule mediators including histamine proteases, and select cytokines via degranulation which trigger rapid and robust physiologic effects such as changes in blood flow, increased endothelial and epithelial permeability, hyper-secretion and immune cell activation and recruitment (1–6). While stress-induced MC degranulation and the associated tissue pathophysiology likely represents an critical host defense strategy to mobilize critical resources for the fight or flight response and enhance immune function, excessive MC activation can be detrimental and has been linked with the onset and severity of diseases including allergy, asthma and IBS (7–11).

The CRF system is well-established as a major stress regulatory system in the body (12) and is composed of a family of peptides related CRF and related family of urocortins (Ucn I-III) which mediate their actions via GPCR's CRF<sub>1</sub> and CRF<sub>2</sub>. The role of the CRF system has been extensively studied in the CNS with regards to HPA axis regulation and neurobehavioral paradigms (12, 13). More recently, the CRF system has been shown to be highly active in peripheral immunological and infectious challenge conditions (14–17), suggesting an important role in immune function. Comparatively, little known about the role of the CRF system in regulating the function of specific immune cells such as the MC. MCs express both CRF<sub>1</sub> and CRF<sub>2</sub> (18–20) and can synthesize and release ligands CRF and Ucn (21, 22). Pharmacological stimulation of CRF receptors on human and rodent MCs *in vitro* was shown to induce canonical GPCR signaling pathways, such as cAMP Ca<sup>2+</sup> and pERK, and the selective release of *de novo* synthesized growth factors and cytokines (18, 19, 23), whereas CRF receptor ligands did not induce degranulation. The *in vivo* role of MC-expressed CRF receptors has remained elusive; however, we recently demonstrated that CRF<sub>1</sub> expressed on MCs acts as a positive modulator of stress-induced MC degranulation and associated tissue pathophysiology in response to anaphylaxis and psychological stress (22). In the present study, we demonstrate that the complementary CRF receptor subtype, CRF<sub>2</sub>, is a negative modulator of MC degranulation and associated pathophysiological responses to immunological and psychological stressors, thus further supporting a critical

homeostatic role for the MC-specific CRF system in mast cell activation and MC-associated diseases.

## METHODS

### Ethics statement

All protocols were approved by the North Carolina State University (Protocol 09-047B) and Michigan State University's Institutional Animal Care and Use Committee (Protocol 03/15-039-00).

### Animals

Founding breeders for all mice strains were obtained from the Jackson Laboratories (Bar Harbor, ME) and were housed in accordance with guidelines from the American Association for Laboratory Animal Care and Research Protocols. C57BL/6 (Stock no. 000664) and *Kit<sup>W-sh/W-sh</sup>* mice (Stock no. 012861) used in this study were derived from homozygous breeders. Heterozygous CRF<sub>2</sub><sup>+/-</sup> mice (B6; 129-*Crhr2<sup>tm1Jsp/J</sup>*; Stock no. 010842) were purchased and bred to obtain wild-type CRF<sub>2</sub><sup>+/+</sup> and knockout CRF<sub>2</sub><sup>-/-</sup> mice. The knockout CRF<sub>2</sub><sup>-/-</sup> mice have three exons, which encode for the third intracellular loop of CRF<sub>2</sub> cytoplasmic region, replaced with a neomycin resistance cassette as described earlier (24). Standard PCR was used to genotype and confirm WT and CRF<sub>2</sub><sup>-/-</sup> mice and BMMCs confirm both in house and via commercial services (GeneTyper, New York, New York) using PCR protocols published at [www.jax.org](http://www.jax.org).

### Passive systemic anaphylaxis

Wildtype and CRF<sub>2</sub><sup>-/-</sup> female mice (8 weeks of age) were sensitized by intraperitoneal injection (i.p.) with 20 µg of IgE monoclonal anti-dinitrophenyl in 100 µl PBS. The following day, mice were challenged with 1 mg of DNP in 100 µl PBS (i.p.). The mice were constantly observed and rectal body temperature recorded for 0, 15, 30, 60 and 120 minutes post DNP challenge (TH-5 Thermalert, Physitemp, Clifton, NJ). Mice were sacrificed at 0 min and 30 min post-DNP injection for serum collection via cardiac puncture and stored at -80°C until serum histamine level was quantified using a commercial EIA kit (Oxford Biomedical Research). *Antalarmin experiments*: PSA was performed as indicated above with the additional treatment group of antalarmin-treated CRF<sub>2</sub><sup>-/-</sup> mice. Antalarmin (15 mg/kg) was injected (i.p.) in to male mice 15 minutes prior to DNP challenge. Mice were sacrificed 30 min post-DNP injection and plasma was collected via cardiac puncture for later histamine analysis.

### Histamine measurements

Histamine concentrations were quantified in serum, plasma, and in cell pellets and supernatants from stimulated MC cultures with a histamine EIA kit (Oxford Biomedical Research, Rochester Hills, MI).

### Quantification of tissue mast cell numbers

Small intestinal mesentery windows from wildtype and CRF<sub>2</sub><sup>-/-</sup> mice were whole mounted on glass slides and fixed with Carnoy's fixative and stained with Toulidine blue as described previously (25). The heart and ear from the same mice were fixed in 4% paraformaldehyde embedded in paraffin, deparaffinized sections were stained with Toluidine blue. Toluidine blue stained mast cells were counted in five, non-overlapping microscopic fields at a magnification of 400x. Each field contained tissue sections that filled the entire hpf. Mesentery mast cells were counted in at least six mesenteric windows per mouse (n=4/genotype). Prior to performing tissue counts, each slide was coded so that counts were performed in a blinded manner. The average number of mast cells per high power field (hpf) was then calculated for each tissue and within each genotype.

### White Blood Cell Differential Count

Blood was collected via cardiac puncture from wildtype and CRF<sub>2</sub><sup>-/-</sup> female mice and placed into EDTA-treated tubes (Microvette, Nümbrecht, Germany). Blood smears were performed followed by a differential white blood cell count (# basophils/100 WBCs).

### Ussing chamber studies

Distal small intestine (ileum) was harvested from each mouse immediately after euthanasia and opened along the anti-mesenteric border. The intestinal mucosa was stripped from the seromuscular layer in oxygenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) Ringer solution (in mmol/l: 154 Na<sup>+</sup>, 6.3 K<sup>+</sup>, 137 Cl<sup>-</sup>, 0.3 H<sub>2</sub>PO<sub>4</sub>, 1.2 Ca<sup>2+</sup>, 0.7 Mg<sup>2+</sup>, 24 HCO<sub>3</sub><sup>-</sup>; pH 7.4) and mounted in 1.13 cm<sup>2</sup> aperture Ussing chambers (World Precision Instruments, Inc., Sarasota, FL). Ileal mucosa was bathed on the serosal and mucosal sides with 10 ml Ringer's solution. The serosal bathing solution contained 10 mM glucose, which was osmotically balanced on the mucosal side with 10 mM mannitol. Bathing solutions were oxygenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) and circulated in water-jacketed reservoirs maintained at 37°C. The spontaneous potential difference (PD) was measured using Ringer-agar bridges connected to calomel electrodes, and the PD was short-circuited through Ag-AgCl electrodes using a voltage clamp that corrected for fluid resistance. Tissues were maintained in the short-circuited state, except for brief intervals to record the open-circuit PD. Transepithelial electrical resistance (TER, measured as  $\times\text{cm}^2$ ) was calculated from the spontaneous PD and short-circuit current ( $I_{sc}$ ), as previously described(26). After a 30-min equilibration period on the Ussing chambers, TER was recorded at 15 min intervals over a 1-h period and then averaged to derive the basal TER values for a given animal. After a 30 min equilibration period on Ussing chambers, FD4 (Sigma, 100 mg/ml) was added to the mucosal bathing reservoir of the Ussing chambers. After a 15 min equilibration period, standards were taken from the serosal side of each chamber and a 60 min flux period was established by taking 0.5 ml samples from the mucosal compartment. The quantity of FD4 was established by measuring the fluorescence in mucosal reservoir fluid samples in a fluorescence plate reader at 540 nm. Data are presented as the rate of FD4 flux in ng FD4.min.cm<sup>2</sup>

### Culture of bone marrow derived mast cells (BMMCs) and RBL-2H3 cells

Bone marrow cells derived from female WT and CRF<sub>2</sub><sup>-/-</sup> mice of approximately 4–6 weeks of age. Isolated bone marrow progenitor cells were cultured in RPMI 1640 media (with L-glutamine) supplemented with FBS (10%), sodium pyruvate (1 mM), MEM nonessential amino acids (1X), HEPES buffer (10 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) and recombinant cytokines [stem cell factor (5 ng/ml) and interleukin-3 (5 ng/ml)]. After four weeks, cultures comprised mainly of mast cells (93%) as determined by toluidine blue (Sigma-Aldrich, St. Louis, MO) staining, and flow cytometry analysis (BD LSR II, East Lansing, MI) using fluorescently labeled c-Kit (Biolegend, San Diego, CA), high-affinity IgE receptor (FcεRI) antibodies (eBioscience, San Diego, CA) and CRF<sub>2</sub> anti-Rabbi. Media and supplements were purchased from Corning Cellgro (Manassas, VA) and recombinant cytokines from R&D Systems (Minneapolis, MN). The rat basophilic leukemia cell MC line (RBL-2H3) were grown in MEM media with 10% fetal bovine.

### Confocal immunofluorescence staining

BMMCs and peritoneal mast cells were obtained from 8 week old female c57Bl/6 mice as previously described (25). Cells were pelleted, washed once with 1x PBS, cytospun onto slides, and fixed with 4% PFA for 20 minutes at 4°C. Slides were blocked at room temperature for 1 hour with blocking buffer (10% normal donkey serum, 0.3% Triton X-100) in 1x PBS, permeabilized (0.1% triton x100), and incubated with goat anti-CRF<sub>1</sub> (Novus Biologicals, NBP1–00175) and rabbit anti-CRF<sub>2</sub> (Novus Biologicals, NBP100–56485) in dilution buffer at a concentration of 1:100 diluted in 1% BSA in a humidified chamber overnight at 4°C. Slides were washed three times for five minutes and then incubated in with anti-rabbit-Cy3 and anti-goat-FITC secondary antibodies in dilution buffer (1:300) for 1 hour at room temperature in the dark. Slides were washed three times for 5 minutes with 1x PBS and ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher, P36971) was added prior to being cover-slipped. Confocal images were obtained with Olympus FV 1000 confocal laser scanning microscope, (Olympus America, Center Valley, PA).

### β-Hex assay

RBL 2H3 cells or murine BMMCs ( $2 \times 10^6$  cells/ml) were sensitized overnight at 37°C with 1 µg/ml anti-dinitrophenyl (DNP)-IgE (Sigma-Aldrich) in complete RPMI medium with cytokines. The following day cells were washed and resuspended in Tyrode's buffer and BMMCs were seeded in a 96 well plate ( $0.45 \times 10^6$  cells/well). The cells were equilibrated for an hour and stimulated with indicated concentrations of dinitrophenyl-albumin (DNP) (Sigma-Aldrich) for 1 h at 37°C. For A23187 and c48/80 stimulation, unsensitized BMMCs were stimulated for 1 h. β-Hex activity was measured by addition of p-nitrophenol-N-acetyl-α-D-glucosaminide in 0.1 M sodium citrate (pH 4.5) for 1 hour at 37°C. The reaction was terminated with 0.1 M carbonate buffer (pH 10.0) and the absorbance was recorded at 405 nm. The percent degranulation was calculated by dividing optical absorbance of the supernatant by the sum of optical absorbance by the supernatant and cell pellet (lysed with 0.1% Triton X-100) and multiplying by 100.

### CRF<sub>2</sub> over-expression and knockdown in RBL-2H3 MCs

Lenti ORF clone of CRF<sub>2</sub> (*CRHR2*), transcript variant 1, and mGFP tagged plasmid were obtained from Origene (Rockville, MD) (Cat No: RG222881). CRF<sub>2</sub> shRNA clone (MSH028936-LVRU6MH) were purchased from GeneCopoeia (Rockville, MD). DH5 alpha competent cells were obtained from Invitrogen (Cat no: 18265017) and the plasmids were transfected and plated on selective antibiotic resistance LB plates according to the manufacturers protocol. After overnight incubation at 37°C, a single colony was picked for each individual clones and inoculated on 2.5 ml LB media containing antibiotics and kept for 8 hours at 37°C at 200 rpm. A total of 600 µl of culture inoculum was transferred in to 300 ml of LB broth on a sterile 1 L flask with antibiotics and kept at 200 rpm at 37°C overnight. Plasmid was extracted and the concentration was measured according to the manufacturer's protocol (Qiagen Cat No: 12662).

Human embryonic kidney cell 293Ta lentivirus cells were seeded at a concentration of  $1.5 \times 10^6$  cells per well (6 well) and 2.5 µg of CRF<sub>2</sub> over-expressed or CRF<sub>2</sub> shRNA along with respective control eGFP or Scrambled shRNA plasmid control DNA were transfected using Lentiviral packaging kit (Origene Cat No: TR30022) according to manufacturer's protocol. After overnight incubation at 37°C with 5% CO<sub>2</sub>, the transfection media was replaced with normal 5% DMEM media with polybrene (1 µl of 4 mg/ml). 48h after transfection, the supernatant was collected from the 6 well plate and filtered onto a Nalgene ultracentrifuge tube and 5 ml of 20% sucrose was added into the bottom of the tube. Centrifuged at 25,000 rpm for 2 hour at 4°C and the supernatant was discarded and the lentiviral over-expressing CRF<sub>2</sub> plasmid or CRF<sub>2</sub> shRNA, pellet was re-suspended with 150 µl of 4% lactose and kept on ice for 15 min and centrifuged at a high speed for 1 min. Lentiviral aliquots were stored at -80°C until transfection.

Lentivirus titrating was done and RBL-2H3 at a concentration of  $2.5 \times 10^5$  cells were plated on a 12 well plate and grown over night. Lentivirus over expressing *CRHR2* or CRF<sub>2</sub> shRNA plasmid at MOI of 40 and polybrene at a final concentration of 8 µg/ml was added in to each well and centrifuged the plate at 300 g for 60 min at 30°C. The plate was incubated at 37°C for overnight and the media was replaced with 15% MEM. After 48 h of transfection, the cells were trypsinized and transferred onto T75 flasks. The RBL-2H3 over expressing CRF<sub>2</sub> or CRF<sub>2</sub> shRNA tagged with GFP (CRF<sub>2</sub> Over expressed) or mCherry (CRF<sub>2</sub> shRNA) were sorted on the flow cytometry (Becton Dickinson FACSAria II, UNC, Chapel Hill, NC) based on the GFP or mCherry positive cells and multiplied and the RBL-2H3 cell aliquots were stored at liquid nitrogen for further study.

### CRF<sub>2</sub> siRNA knockdown in RBL-2H3 cells

Overnight grown RBL-2H3 cells were seeded at a concentration on  $5 \times 10^5$  in a 6 well plate were transfected with CRF<sub>2</sub> siRNA (NM-022714, sigma) or scrambled siRNA (SIC00-1, sigma) of 150 ng using Qiagen Hi-perfect transfection reagent according to its manufacturer's protocol. Six hours post transfection normal growth media added to each well and incubated at 37°C with 5% CO<sub>2</sub> for 48 hour. After the incubation, transfected cells were primed with over-night IgE or not and stimulated with 1 hour DNP or A23187 (non

IgE primed) and the  $\beta$  hexosaminidase, histamine and calcium mobilization assay was done as described above.

### Human mast cell experiments with LAD2 cells

LAD2 cells provided by A. Kirshenbaum (NIH, USA) were cultured in StemPro-34 (Life Technologies, Carlsbad, CA) media supplemented with StemPro-34 Nutrient Supplement ((Life Technologies) l-Glutamine (2 mM) ((Life Technologies), Penicillin (100 U/ml)/ Streptomycin (100  $\mu$ g/ml) and rhSCF (Peprotech Inc., Rocky Hill, NJ) (100 ng/ml). Cell density was kept below  $0.5 \times 10^6$ /ml. and half the amount of media was replaced weekly. Cells were sensitized overnight with 100 ng/ml biotinylated human IgE (US Biologicals). On the following day, cells were washed with Tyrode's buffer to remove excess IgE and stimulated with (vehicle, 0.1% BSA in PBS), streptavidin (100 ng/ml), and 1–100 nM of human Astressin 2B (A2B) (kind gift from Jean Rivier, The Salk Institute, La Jolla, CA). Release of  $\beta$  hexosaminidase was measured after 1 hour of stimulation as described above.

### RT-PCR

Total RNA was extracted from heart tissue and BMMCs using TRIzol Reagent (Invitrogen) followed by DNase treatment and purification using the PureLink RNA mini kit (Life Technologies). cDNA was synthesized and amplified using the SuperScript® III One-Step RT-PCR System with CRF<sub>2</sub> specific primers (5'-TCGGGCAGGGTAGGACAG-3' and 5'-CGGGCAGACGGTGACAGA-3') designed to include the full mouse CRF<sub>2</sub> coding region (Sztainberg et al., 2009). Total RNA was isolated from RBL-2H3 cells using Qiagen RNAeasy kit and transcribed to cDNA using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). CRF<sub>2</sub> expression was determined using CRF<sub>2</sub> specific primers (Forward Rat 1\_Crhr2: ACTCTACTATGAGAATGAGCAG and Reverse Rat 1\_Crhr2: TGACGATGTTGAACAGAAAC; Sigma-Aldrich).

### Intracellular Ca<sup>2+</sup> measurements

RBL-2H3 cells and murine BMMCs derived from WT and CRF<sub>2</sub><sup>-/-</sup> mice were used for this study. On the day of the experiment, cells were washed and re-suspended in calcium assay buffer. Changes in intracellular calcium in response to stimulus were detected using the Fluo 4 NW Calcium assay kit (Thermo Fisher Scientific) according to manufacturer's instructions. Briefly, cells were loaded at 37 °C for 30 min with the fluorescent Ca<sup>2+</sup> indicator, Fluo 4 NW, in the presence of Probenecid, followed by incubation at room temperature for another 30 min. Changes in fluorescence was measured by stimulating the cells by adding different concentrations of DNP/HSA or A2187 or c48/80. Change in fluorescence was measured using the FDSS/ $\mu$ CELL kinetic plate reader (hamamatsu) or Fluoroskan Ascent FL microplate reader (Thermo Fisher Scientific) at 480 nm excitation and 540 nm emission. The ratio was calculated by average increase in fluorescence divided with the baseline was determined for each time point after the addition of stimulus.

### Store operated Ca<sup>2+</sup> entry (SOCE) channel expression

BMMC lysates were prepared by re-suspending cells in RIPA buffer (Thermo Fisher Scientific) containing protease and phosphatase inhibitors (Thermo Fisher Scientific) at 4°C.



Lysates were sonicated and centrifuged at 21,000 x g for 10 min. The protein concentration was measured using DC Protein Assay Kit (Bio-Rad). Cellular proteins were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membranes were blocked with 5% w/v BSA in Tris-buffered saline (TBS) with 0.1% Tween 20 (TBS-T) for 1 hour at room temperature, washed in TBS-T, incubated with the following Rabbit Anti-Human antibodies: STIM1 (alomone labs #ACC-063;1:500 dilution), Anti-TRPC1 (alomone labs #ACC-010;1:600 dilution), Anti-Orai1 (alomone labs #ACC-060;1:400 dilution), and  $\beta$ -actin (cell signaling, 4970, 1:1000) diluted in 5% w/v BSA in TBS-T for overnight at 4°C or 2 hours at room temperature, and then washed with TBS-T. Subsequently, the membranes were incubated with rabbit polyclonal secondary antibody (cell signaling 7074; 1:2000) for 1 hour at room temperature, washed with TBS-T and incubated in SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). Bands were visualized with ChemiDoc MP Imager (Bio-Rad Laboratories) and the Image Lab software (version 4.1) was used for densitometric analysis.

### Restraint stress model

Female mice were placed in individual transparent 50 ml plastic conical tubes, modified with air holes, for a 3 h period. Control mice remained in their original home cages for 3 h without food and water to avoid confounding effects of water or feed intake during the 3 h experimental period. Following RS, mice were immediately euthanized by CO<sub>2</sub> inhalation, and serum and ileal mucosa were collected for measurement of serum histamine and intestinal permeability, respectively.

### BMMC engraftment in *Kit<sup>W-sh/W-sh</sup>* mice

Female *Kit<sup>W-sh/W-sh</sup>* mice (8–10 weeks of age) were injected intraperitoneally with  $1 \times 10^7$  BMMCs (suspended in 200  $\mu$ l of sterile 1x PBS) derived from CRF<sub>2</sub><sup>+/+</sup> (WT) or CRF<sub>2</sub><sup>-/-</sup> mice. At 16 weeks of age (4 weeks post-engraftment), engrafted mice were sacrificed by CO<sub>2</sub> inhalation. Intestinal mesentery window sections were harvested fixed in Carnoy's fixative and stained with Toluidine blue to confirm engraftment of BMMCs.

### Statistical analysis

*In vivo* and *in vitro* studies are presented as means  $\pm$  SE from a representative experiments with an n=6–8 animals/treatment group (unless otherwise specified). Experimental results were repeated in a minimum of 2 independent experiments while some experiments were repeated in greater than 2 independent experiments (noted in figure legends). Comparisons between multiple experimental groups was performed using a 1 or 2-Way ANOVA where appropriate with a Tukey's post-test. Comparisons between two treatments were analyzed using an unpaired two-tailed *t* test. Values of  $p < 0.05$  were considered statistically significant. All statistical analyses and calculations were performed using GraphPad Prism 5 software (San Diego, CA, USA).

## RESULTS

### CRF<sub>2</sub>-deficiency exacerbates PSA-induced mast cell degranulation, anaphylaxis and intestinal permeability

To first define the role of CRF<sub>2</sub> in MC-associated disease *in vivo*, we compared MC responses and associated pathophysiology in a MC-dependent model of PSA. Compared with WT mice, CRF<sub>2</sub><sup>-/-</sup> mice exhibited higher (by 4.1 fold) serum histamine levels, measured at 30 min post-PSA challenge (5017 ± 919 ng/ml and 1208 ± 235 ng/ml in CRF<sub>2</sub><sup>-/-</sup> and WT mice, respectively,  $P < 0.001$ , Fig. 1A). In agreement with serum histamine levels, CRF<sub>2</sub><sup>-/-</sup> mice exhibited a greater peak reduction in body temperature measured at 30 minutes post-DNP challenge (−4.55 ± 0.85°C and −6.8 ± 0.54°C in WT and CRF<sub>2</sub><sup>-/-</sup> mice, respectively,  $P = 0.04$ , Fig. 1B). Measurement of cardiac blood volume reduction, an index of systemic vasodilation and fluid extravasation induced by PSA (27, 28), was also greater in CRF<sub>2</sub><sup>-/-</sup> mice at 30 and 120 min post-DNP challenge, compared with WT mice (Fig. 1C), thus indicating a more severe hypovolemic shock response in CRF<sub>2</sub><sup>-/-</sup> mice. Intestinal permeability, measured as increased FD4 flux rate and reduced TER across ileal mucosa mounted on Ussing chambers, was greater in CRF<sub>2</sub><sup>-/-</sup> mice compared with WT mice 120 min post-PSA (Fig. 1D, E). Quantification of tissue MCs by Toluidine blue staining of heart, intestinal mesentery and skin showed that WT and CRF<sub>2</sub><sup>-/-</sup> mice had similar distributions and numbers of tissue MCs (Fig. 1F-H). Further, circulating basophil numbers were similar between WT and CRF<sub>2</sub><sup>-/-</sup> confirming that elevated histamine levels in CRF<sub>2</sub><sup>-/-</sup> mice, were not due to increased basophil numbers. Given that many mast cell-dependent diseases exhibit a female sex bias and our previous studies demonstrating sex differences in mast cell responses (25), we also compared the influence of CRF<sub>2</sub> deficiency on PSA-induced serum histamine responses in female and male mice. These studies confirmed our previous research showing that females exhibit a greater release of serum histamine compared with males, CRF<sub>2</sub><sup>-/-</sup> deficiency exacerbated serum histamine responses in both female and male mice (Supplemental Fig 1). Therefore, we conducted subsequent experiments in predominantly in female mice. Together, these experiments revealed a significant *in vivo* role for CRF<sub>2</sub> in IgE-mediated MC degranulation, anaphylaxis and intestinal permeability.

### CRF<sub>2</sub> expressed on MCs is a negative modulator of MC degranulation

Corticotropin releasing factor receptors are widely expressed in numerous cell types, including MCs (20, 29, 30), but little is known regarding the localization or functional role of CRF<sub>2</sub> in MC function. Using confocal microscopy, CRF<sub>2</sub> was found to be localized to the both the surface and intracellularly in BMMCs and peritoneal (tissue) mast cells (Fig. 2). Further, a nuclear staining pattern of CRF<sub>2</sub> was also observed predominantly in BMMCs compared PMCs. Flow cytometry confirmed the surface expression of CRF<sub>2</sub> in BMMCs (Supplemental Fig. 2G). CRF<sub>1</sub> showed a different pattern of expression with a predominant surface localization in PMCs and BMMCs with some intracellular staining was observed mostly in BMMCs. To explore the functional role of MC CRF<sub>2</sub><sup>-/-</sup>, we conducted *in vitro* degranulation assays with BMMCs derived from WT and CRF<sub>2</sub><sup>-/-</sup> mice. In line with *in vivo* PSA studies, CRF<sub>2</sub><sup>-/-</sup> BMMCs exhibited exacerbated degranulation responses measured as enhanced β-hex release following IgE-FcεR1 cross-linking (Fig. 3A). Transmission electron microscopy (TEM) revealed a more activated appearance of CRF<sub>2</sub><sup>-/-</sup> BMMCs following

IgE/DNP, compared with WT BMMCs, thus supporting  $\beta$ -hex data (Fig. 3D). To determine whether the exacerbated MC degranulation responses observed in  $CRF_2^{-/-}$  BMMCs were specific to IgE-Fc $\epsilon$ R1-mediated pathways, WT and  $CRF_2^{-/-}$  BMMCs were also stimulated with non-IgE dependent MC stimuli including the c48/80, which acts via the G-protein coupled receptor, Mrgpb2 (31), and A23187, which acts on downstream SOCE mechanisms from intracellular (e.g. endoplasmic reticulum, ER) and extracellular stores (32). Similar to IgE stimulus,  $CRF_2^{-/-}$  BMMCs exhibited exacerbated  $\beta$ -hex release in response to both A23187 and c48/80 (Fig. 3 B, C). Because our previous work demonstrated that  $CRF_1$  potentiates stimuli-induced mast cell degranulation (22), we investigated whether enhanced degranulation in  $CRF_2^{-/-}$  BMMCs could be due to a reciprocal upregulation of  $CRF_1$  expression. Quantitative PCR showed that compared with WT BMMCs,  $CRF_2$  expression was down-regulated in  $CRF_2^{-/-}$  BMMCs (by ~ 40%) but  $CRF_1$  expression was not significantly altered (Supplemental Fig. 3 A,B). It should be noted that because the loss of  $CRF_2$  activity in  $CRF_2^{-/-}$  BMMCs (derived from  $CRF_2^{-/-}$  mice) is a result of a functional deletion of a c-terminal region,  $CRF_2$  is still expressed as shown in Supplemental Fig. 3A, but at a lower level than WT BMMCs. There were no significant differences between WT and  $CRF_2^{-/-}$  BMMCs with regards to the cellular content of  $\beta$ -hex content or phenotype determined by c-kit/Fc $\epsilon$ R1 expression by flow cytometry analysis (Supplemental Fig. 2), confirming that enhanced degranulation in  $CRF_2^{-/-}$  BMMCs were not due to an increased intracellular granule mediator content or aberrant MC phenotype.

To further examine the link between  $CRF_2$  expression on MCs and degranulation responses, we transfected  $CRF_2$ -plasmid into RBL-2H3 MCs to enhance  $CRF_2$  expression. We confirmed the specificity of the  $CRF_2$ -over expression by qPCR which revealed and upregulation of  $CRF_2$  expression (by 6.4 Fold; Supplemental Fig. 3C) compared with the empty GFP (eGFP) plasmid, while having no significant effect on  $CRF_1$  expression (Supplemental Fig. 3D).  $CRF_2$  over-expressed RBL-2H3 MCs exhibited suppressed IgE/DNP-mediated  $\beta$ -hex release (by 47%), compared with empty plasmid controls (Fig. 3E). We also knocked down  $CRF_2$  expression in RBL-2H3 MCs with  $CRF_2$ -directed siRNA, which resulted in a 2-fold increase in  $\beta$ -hex release following IgE/DNP stimulation, compared with scrambled siRNA controls (Fig. 3F). Pharmacological inhibition of  $CRF_2$  with the selective antagonist Astressin 2b (A2B) enhanced IgE-Fc $\epsilon$ R1-induced  $\beta$ -hex release in both rat RBL-2H3 and human LAD2 MCs (Fig. 5), thus confirming the genetic experiments and translational significance to human MCs.

Given our previous work showing that MC  $CRF_1$  potentiates MC degranulation while in the present study  $CRF_2$  suppresses MC degranulation, we hypothesized that MC  $CRF_1$  and  $CRF_2$  might function in concert to regulate or balance MC degranulation responses. To test this hypothesis, we pre-treated  $CRF_2^{-/-}$  mice with the  $CRF_1$  selective antagonist Antalarmin followed by induction of IgE-mediated PSA. Antalarmin significantly attenuated the exacerbated PSA-induced histamine release in  $CRF_2^{-/-}$  mice (Supplemental Fig. 4).

### **$CRF_2$ negatively regulates SOCE in MCs**

We next explored the mechanism by which  $CRF_2$  caused suppression of stimuli-induced MC degranulation. Because  $CRF_2$  was shown to negatively modulate MC degranulation induced

by diverse MC stimuli that utilize upstream, receptor-dependent pathways (IgE-FcεR1, and c48/80) or downstream, receptor-independent pathways (A23187) mechanisms, we hypothesized that CRF<sub>2</sub> was targeting a common downstream signaling mechanism utilized by MC degranulation stimuli. SOCE from intracellular (endoplasmic reticulum and golgi) and extracellular stores is essential for MC granule exocytosis and degranulation (33). Therefore, we conducted Ca<sup>2+</sup> mobilization experiments with WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs loaded with the Fluo 4 Ca<sup>2+</sup> indicator dye. These experiments showed that CRF<sub>2</sub><sup>-/-</sup> BMMCs exhibited heightened IgE/DNP Ca<sup>2+</sup> mobilization following IgE/DNP stimulation (Fig. 5). Furthermore, CRF<sub>2</sub><sup>-/-</sup> BMMCs also exhibited heightened Ca<sup>2+</sup> signaling in response to other MC stimuli including A23187, c48/80 and the muscarinic 3 receptor agonist carbachol (Fig. 5) overall demonstrating the global inhibitory role of CRF<sub>2</sub> in response to diverse MC stimuli.

We next conducted similar experiments in Ca<sup>2+</sup>-replete or Ca<sup>2+</sup>-free conditions (1 mM EDTA) to determine whether the heightened Ca<sup>2+</sup> signaling in CRF<sub>2</sub><sup>-/-</sup> BMMCs was due to enhanced release from intracellular stores such as the ER or via influx of extracellular Ca<sup>2+</sup> via plasma membrane channels. As anticipated, removal of extracellular Ca<sup>2+</sup> with EDTA significantly reduced Ca<sup>2+</sup> signals induced by IgE/DNP in both WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs (Fig. 6A, B). However, EDTA did not ablate the heightened Ca<sup>2+</sup> signaling in CRF<sub>2</sub><sup>-/-</sup> BMMCs, compared with WT BMMCs (Fig. 6B, C) indicating heightened Ca<sup>2+</sup> release from intracellular stores in CRF<sub>2</sub><sup>-/-</sup> BMMCs. CRF<sub>2</sub><sup>-/-</sup> BMMCs also exhibited increased expression of SOCE channels including the ER Ca<sup>2+</sup> sensor stromal interacting molecule-1 (STIM1), and plasma membrane channels transient receptor potential canonical-1 (TRPC1) and Orai1 (Fig. 6D-I). Together these data indicate that CRF<sub>2</sub> is a negative and global modulator of stimuli-induced Ca<sup>2+</sup> signaling with actions on intracellular release and subsequent extracellular Ca<sup>2+</sup> entry.

### **CRF<sub>2</sub><sup>-/-</sup> mice exhibit elevated serum MC histamine and intestinal permeability in response to acute restraint stress**

*In vitro* MC culture experiments revealed that MC CRF<sub>2</sub> exerted suppressive effects on MC degranulation induced by a diverse array of potent MC stimuli. Given these findings, we hypothesized that the global effects of CRF<sub>2</sub> on MC degranulation, would extend to non-IgE-dependent *in vivo* models of MC degranulation. To test this hypothesis, we compared MC degranulation responses, via measurement of serum histamine levels, in WT and CRF<sub>2</sub><sup>-/-</sup> mice following a 1-hour period of psychological restraint stress. Compared with WT mice, CRF<sub>2</sub><sup>-/-</sup> mice exhibited higher serum histamine levels following restraint stress (97.7 ± 5.9 ng/ml and 68.2 ± 7 ng/ml in CRF<sub>2</sub><sup>-/-</sup> and WT mice, respectively, *P* < 0.01, Fig. 7A). We also assessed colonic permeability measured as FD4 flux rates on Ussing chambers, which showed a significantly elevated FD4 flux rate in CRF<sub>2</sub><sup>-/-</sup> mice following restraint stress, compared with WT mice. (Fig. 7B). Together, these data indicate that CRF<sub>2</sub> plays a global role in controlling MC degranulation and associated tissue pathophysiology induced by diverse stressors.

## MC CRF<sub>2</sub> is a negative modulator of stress-induced intestinal permeability

The above experiments demonstrated an important role for CRF<sub>2</sub> as a negative modulator of MC-dependent intestinal permeability induced by PSA and restraint stress. Further, *in vitro* experiments demonstrated the role of MC-specific CRF<sub>2</sub> in the control of stimuli-induced mast cell degranulation. We next determined the *in vivo* significance CRF<sub>2</sub> expressed on MCs utilizing a MC knock-in model. MC-deficient *Kit<sup>W-sh/W-sh</sup>* mice were systemically engrafted with BMMCs derived from either WT or CRF<sub>2</sub><sup>-/-</sup> mice. Twelve weeks post-engraftment, mice underwent 3 h of restraint stress and colonic permeability was measured in Ussing chambers. Compared with *Kit<sup>W-sh/W-sh</sup>* mice engrafted with WT BMMCs, CRF<sub>2</sub><sup>-/-</sup> engrafted mice exhibited the greater colonic permeability responses, measured as FD4 flux rates (Fig. 8A). WT and CRF<sub>2</sub><sup>-/-</sup> mice exhibited similar reductions in colonic TER following restraint stress (Fig. 8B). Toluidine blue staining and MC counts in intestinal mesenteric tissue confirmed an equal engraftment rate between WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs in MC-deficient *Kit<sup>W-sh/W-sh</sup>* mice (Fig. 8C).

## DISCUSSION

Stress is an important risk factor in the clinical onset and severity of important immunological disorders including allergy, asthma and functional and inflammatory GI disorders. Mast cells (MCs) play a central role in many immunological disease and have gained recognition as a critical immune effector cell in the stress response. Mast cells are rapidly activated (within minutes) of exposure to diverse stressors including psychological, chemical and physical stressors resulting in the release of preformed granule mediators (e.g. histamine, proteases, TNF, etc.) via degranulation. Released MC mediators evoke profound physiologic effects in local and systemic tissues such as increased epithelial and endothelial permeability, neuronal activation and circulatory changes. While stress-induced MC activation likely represents an early defense or alarm mechanism to mobilize resources necessary for the individual to respond appropriately to the stressor, excessive or prolonged MC activation is harmful leading to immune dysregulation and tissue damage and exacerbation of disease. While the major mast cell stimuli have been identified; how environmental factors such as stress play a role in exacerbating or limiting MC activation remain poorly understood. Here we demonstrated a novel function for CRF<sub>2</sub> expressed on MCs as a negative modulator of stimuli induced MC degranulation and MC-dependent pathophysiology associated with anaphylaxis and acute psychological stress.

Previous studies conducted *in vitro* with human and rodent MCs demonstrated that MC express both CRF<sub>1</sub> and CRF<sub>2</sub> receptors (22, 23) and that CRF receptor ligands can induce canonical GPCR pathways including cAMP and phosphoERK signaling (19, 22, 34). However, the precise role of the MC CRF system modulating MC function and MC-mediated disease pathogenesis has remained elusive. We recently demonstrated that CRF<sub>1</sub> receptor signaling in the MC is a potentiator of stimuli-induced MC degranulation and system and intestinal pathophysiology induced by PSA and psychological restraint stress (35). In the present study, our data revealed that, in contrast to CRF<sub>1</sub>, CRF<sub>2</sub> exerts inhibitor actions on MC degranulation as loss of CRF<sub>2</sub> activity in MCs, via genetic or pharmacological approaches, resulted in enhanced stimuli-induced MC degranulation and

exacerbated responses to PSA and acute restraint stress. Selective inhibition of CRF<sub>1</sub> was shown to reduce PSA-induced MC responses in CRF<sub>2</sub><sup>-/-</sup> mice to the level of WT mice, overall indicating that MC CRF<sub>1</sub> and CRF<sub>2</sub> act in concert to up- and downregulate, respectively the tone of MC degranulation and resultant MC-dependent pathophysiology. Therefore, it is plausible that a disruption of MC CRF<sub>1</sub> and CRF<sub>2</sub> homeostasis could shift the balance between hypo- and hyper-activated MC states and ultimately disease activity.

The broad inhibitory actions of CRF<sub>2</sub> on multiple MC degranulation stimuli and *in vivo* models led us to hypothesize that CRF<sub>2</sub> was targeting a common, downstream mechanism in MC degranulation. Results from the present study demonstrated that MC CRF<sub>2</sub> expression was negatively associated with Ca<sup>2+</sup> mobilization induced by a diverse array of MC stimuli including IgE-antigen, c48/80 and the muscarinic receptor 3 agonist carbachol. The ability of CRF<sub>2</sub> to inhibit Ca<sup>2+</sup> mobilization and degranulation provides supporting evidence that CRF<sub>2</sub> serves as a global regulation of MC activation. Experiments conducted under Ca<sup>2+</sup>-free conditions, further demonstrated that CRF<sub>2</sub> negatively modulated cytosolic Ca<sup>2+</sup> entry from intracellular stores, presumably the ER. The precise signaling pathways by which CRF<sub>2</sub> inhibits intracellular store Ca<sup>2+</sup> release remains to be fully defined. However, results from the present study revealed an increased expression of the ER Ca<sup>2+</sup> sensing protein STIM1, and plasma membrane Ca<sup>2+</sup> channels TRPC1 and Orai, which together represent the Ca<sup>2+</sup> regulatory channels that play essential roles in SOCE and degranulation in MCs (33, 36). Increased expression of STIM1, Orai and TRPC1 have been associated with heightened Ca<sup>2+</sup> mobilization and MC degranulation in food allergen-sensitized rats (37) which is in line with our findings with CRF<sub>2</sub><sup>-/-</sup> BMMCs. The precise contribution of altered Ca<sup>2+</sup> channel expression to CRF-mediated effects on Ca<sup>2+</sup> mobilization and degranulation is unclear. Chronically elevated Ca<sup>2+</sup> channel activity, due to genetic loss of CRF<sub>2</sub> function in CRF<sub>2</sub><sup>-/-</sup> BMMCs, could lead to increase protein expression of STIM1, TRPC1 and Orai1 resulting in heightened MC activity. However, that short-term pharmacological blockade of CRF<sub>2</sub> and transient siRNA approaches were shown to enhance stimuli-induced MC degranulation suggests a more direct signaling event is likely involved.

Confocal microscopy revealed that CRF<sub>2</sub> was localized on the surface of the MC and intracellularly. Further, intra-nuclear expression of CRF<sub>2</sub> was also observed. In comparison, CRF<sub>1</sub> was localized predominantly to the cell surface of MCs with no apparent nuclear staining patterns. Together, these findings demonstrate differential cellular localization patterns between CRF<sub>1</sub> and CRF<sub>2</sub> but the relationship between cellular localization and divergent functions in MC activation requires further investigation. It has become increasingly clear that a number of GPCRs target to the nuclear membrane (38) and can regulate DNA synthesis (39), transcription and gene expression (40) and histone modification (41). To our knowledge, this represents the first evidence for differential localization of CRF receptor subtypes in MCs and further investigations will likely provide insight into the divergent roles that CRF<sub>1</sub> and CRF<sub>2</sub> in MC function and provide valuable insight into approaches for potential therapeutic modulation.

Precisely how the CRF receptor system is regulated to maintain MC homeostasis with regards to degranulation remains to be fully defined. We and others have shown that MCs release CRF<sub>1</sub>/CRF<sub>2</sub> ligands CRF and urocortin under basal and stimulated conditions (21,

22), and that CRF<sub>1</sub> and CRF<sub>2</sub> receptors modulate stimuli-induced MC degranulation *in vitro* in the absence of exogenous ligands. Together, these findings demonstrate that MCs possess a functional CRF system and implicates an autocrine regulation mechanism. Such a system could explain the ability of the MC CRF system to modulate rapid cellular signaling events in the MC such as Ca<sup>2+</sup> mobilization degranulation events. In view of the CRF system as a homeostatic regulator of the stress response, activation CRF<sub>1</sub> in MCs could provide immunological protection by enhancing MC degranulation and subsequent physiological and immunological responses, especially during time of acute stressful challenges. On the other hand, CRF<sub>2</sub> activation may provide a critical homeostatic mechanism by limiting the extent of degranulation and downstream pathophysiology. Dysfunction or imbalance of this system could lead to aberrant MC function and heightened disease states. It has been shown in cultured MCs that CRF<sub>1</sub> and CRF<sub>2</sub> expression levels can be influenced by psychological stress exogenous CRF receptor ligand, Substance P and LPS (18, 20). There is also substantial evidence in humans and in animal models that CRF<sub>1</sub> and CRF<sub>2</sub> expression is altered under pathological conditions such as urticaria (42), colitis (15) (43) and chronic and early life stress (44, 45). The contribution of altered CRF receptor expression vs function in MC-associated disease pathogenesis remains to be fully elucidated.

In summary, the present study highlights a novel role for CRF<sub>2</sub> receptors expressed on MCs as negative modulators of MC degranulation in the acute response to immunological and psychological stress. Given the critical role of MCs as immune sentinels which rapidly respond to diverse stressful stimuli, the MC CRF<sub>2</sub> system may represent a critical control step to limit MC degranulation and disease pathophysiology. Further understanding of the precise mechanism by which CRF<sub>2</sub> controls MC degranulation and associated disease pathophysiology could unveil new therapeutic targets for immune diseases linked with stress and MC hyperactivity such as allergic inflammation and IBS.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENTS

This work was supported by U.S. National Institutes of Health grants R01 HD072968 (to AJM), R21 AI140413 (to AJM), K08/R03 DK097462 (to AJM), R01 DK080787 (to AB) and F30 OD025354 (to EM).

Dr. Adam Moeser is the Matilda R. Wilson Endowed Chair of Large Animal Clinical Sciences at Michigan State University, College of Veterinary Medicine.

Astressin 2B was a kind gift of Dr. Jean Rivier, Sentia Medical Sciences, Inc., Salk Institute for Biological Studies.

The authors gratefully acknowledge Tom Dexheimer PhD, Manager of the Assay Development and Drug Repurposing Core (ADDRC) at Michigan State University for his advice and technical expertise in conducting the Ca<sup>2+</sup> fluorescence analyses. The Authors also gratefully acknowledge Darcy Honke Hulbert for the management of the mouse breeding colonies used in these experiments.

## Abbreviations:

<b>BMMC</b>	(Bone marrow derived mast cell)
<b>CRF<sub>1</sub></b>	(Corticotropin Releasing Factor Subtype 1)

<b>CRF<sub>2</sub></b>	(Corticotropin Releasing Factor Subtype 2)
<b>MC</b>	Mast cell
<b>PMC</b>	(Peritoneal mast cell)
<b>SOCE</b>	(store operated Ca <sup>2+</sup> entry)
<b>WT</b>	(Wild-type)

## REFERENCES

1. Santos J, Benjamin M, Yang PC, Prior T, Perdue MH. Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. *Am J Physiol Gastrointest Liver Physiol* 2000;278(6):G847–54. [PubMed: 10859213]
2. Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. *Gastroenterology* 2002;123(4):1099–108. [PubMed: 12360472]
3. Wallon C, Yang PC, Keita AV, Ericson AC, McKay DM, Sherman PM, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. *Gut* 2008;57(1):50–8. [PubMed: 17525093]
4. Santos J, Saunders PR, Hanssen NP, Yang PC, Yates D, Groot JA, et al. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. *Am J Physiol* 1999;277(2 Pt 1):G391–9. [PubMed: 10444454]
5. Lennon EM, Maharshak N, Elloumi H, Borst L, Plevy SE, Moeser AJ. Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL-10<sup>-/-</sup> mice. *Inflamm Bowel Dis* 2013;19(4):712–9. [PubMed: 23446335]
6. Moeser AJ, Ryan KA, Nighot PK, Blikslager AT. Gastrointestinal dysfunction induced by early weaning is attenuated by delayed weaning and mast cell blockade in pigs. *Am J Physiol Gastrointest Liver Physiol* 2007;293(2):G413–21. [PubMed: 17525151]
7. Heffner KL, Kiecolt-Glaser JK, Glaser R, Malarkey WB, Marshall GD. Stress and anxiety effects on positive skin test responses in young adults with allergic rhinitis. *Ann Allergy Asthma Immunol* 2014;113(1):13–8. [PubMed: 24726195]
8. Andrae DA PD, Drossman DA, Convington PS. Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrhea-predominant irritable bowel syndrome patients. *Healthy and Quality of Life Outcomes* 2013;11(208).
9. Priftis KN, Papadimitriou A, Nicolaidou P, Chrousos GP. Dysregulation of the stress response in asthmatic children. *Allergy* 2009;64(1):18–31. [PubMed: 19132973]
10. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004;126(3):693–702. [PubMed: 14988823]
11. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. *Gut* 2010;59(9):1213–21. [PubMed: 20650926]
12. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. *Annual review of pharmacology and toxicology* 2004;44:525–57.
13. Chrousos GP. Stress and disorders of the stress system. *Nat Rev Endocrinol* 2009;5(7):374–81. [PubMed: 19488073]
14. la Fleur SE, Wick EC, Idumalla PS, Grady EF, Bhargava A. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. *Proc Natl Acad Sci U S A* 2005;102(21):7647–52. [PubMed: 15883387]
15. Liu Y, Fang X, Yuan J, Sun Z, Li C, Li R, et al. The role of corticotropin-releasing hormone receptor 1 in the development of colitis-associated cancer in mouse model. *Endocrine-related cancer* 2014;21(4):639–51. [PubMed: 25015995]




16. Boyer PE, D'Costa S, Edwards LL, Milloway M, Susick E, Borst LB, et al. Early-life dietary spray-dried plasma influences immunological and intestinal injury responses to later-life *Salmonella typhimurium* challenge. *Br J Nutr* 2015;113(5):783–93. [PubMed: 25671331]
17. Mahajan S, Liao M, Barkan P, Takahashi K, Bhargava A. Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk. *Peptides* 2014;54:58–66. [PubMed: 24462512]
18. Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, et al. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. *J Invest Dermatol* 2012;132(2):324–9. [PubMed: 22089831]
19. Cao J, Cetrulo CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. *Mol Pharmacol* 2006;69(3):998–1006. [PubMed: 16332989]
20. Papadopoulou NG, Oleson L, Kempuraj D, Donelan J, Cetrulo CL, Theoharides TC. Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. *Journal of molecular endocrinology* 2005;35(3):R1–8. [PubMed: 16326828]
21. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 2004;145(1):43–8. [PubMed: 14576187]
22. Ayyadurai S, Gibson AJ, D'Costa S, Overman EL, Sommerville LJ, Poopal AC, et al. Frontline Science: Corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology. *Journal of leukocyte biology* 2017.
23. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *Journal of immunology (Baltimore, Md : 1950)* 2005;174(12):7665–75.
24. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, et al. Deletion of *crhr2* reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. *Nat Genet* 2000;24(4):415–9. [PubMed: 10742109]
25. Mackey E, Ayyadurai S, Pohl CS, S DC, Li Y, Moeser AJ. Sexual dimorphism in the mast cell transcriptome and the pathophysiological responses to immunological and psychological stress. *Biol Sex Differ* 2016;7:60. [PubMed: 27895892]
26. Argenzio RA, Liacos JA. Endogenous prostanoids control ion transport across neonatal porcine ileum in vitro. *AmJVetRes* 1990;51(5):747.
27. Bergman RK, Munoz J. CIRCULATORY COLLAPSE IN ANAPHYLAXIS AND HISTAMINE TOXICITY IN MICE. *Journal of immunology (Baltimore, Md : 1950)* 1965;95:1–8.
28. Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. *Anaesthesia and intensive care* 1986;14(1):17–21. [PubMed: 2869715]
29. Chatzaki E, Anton PA, Million M, Lambropoulou M, Constantinidis T, Kolios G, et al. Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis. *World J Gastroenterol* 2013;19(9):1416–23. [PubMed: 23539366]
30. Yuan PQ, Wu SV, Pothoulakis C, Tache Y. Urocortins and CRF receptor type 2 variants in the male rat colon: gene expression and regulation by endotoxin and anti-inflammatory effect. *Am J Physiol Gastrointest Liver Physiol* 2016;310(6):G387–98. [PubMed: 26744472]
31. Kashem SW, Subramanian H, Collington SJ, Magotti P, Lambris JD, Ali H. G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes *MrgX1* and *MrgX2*. *Eur J Pharmacol* 2011;668(1–2):299–304. [PubMed: 21741965]
32. Dedkova EN, Sigova AA, Zinchenko VP. Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. *Membr Cell Biol* 2000;13(3):357–68. [PubMed: 10768486]
33. Holowka D, Wilkes M, Stefan C, Baird B. Roles for  $Ca^{2+}$  mobilization and its regulation in mast cell functions: recent progress. *Biochemical Society transactions* 2016;44(2):505–9. [PubMed: 27068962]


34. Balseiro-Gomez S, Flores JA, Acosta J, Ramirez-Ponce MP, Ales E. Identification of a New Exo-Endocytic Mechanism Triggered by Corticotropin-Releasing Hormone in Mast Cells. *Journal of immunology* (Baltimore, Md : 1950) 2015;195(5):2046–56.
35. Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, et al. Neurotensin and CRH interactions augment human mast cell activation. *PLoS One* 2012;7(11):e48934. [PubMed: 23155429]
36. Suzuki R, Liu X, Olivera A, Aguiniga L, Yamashita Y, Blank U, et al. Loss of TRPC1-mediated Ca<sup>2+</sup> influx contributes to impaired degranulation in Fyn-deficient mouse bone marrow-derived mast cells. *Journal of leukocyte biology* 2010;88(5):863–75. [PubMed: 20571036]
37. Yang B, Yang C, Wang P, Li J, Huang H, Ji Q, et al. Food allergen--induced mast cell degranulation is dependent on PI3K-mediated reactive oxygen species production and upregulation of store-operated calcium channel subunits. *Scandinavian journal of immunology* 2013;78(1):35–43. [PubMed: 23672459]
38. Vaniotis G, Allen BG, Hébert TE. Nuclear GPCRs in cardiomyocytes: an insider's view of  $\beta$ -adrenergic receptor signaling. *American journal of physiology Heart and circulatory physiology* 2011;301(5):H1754–H64. [PubMed: 21890692]
39. Watson PH, Fraher LJ, Natale BV, Kisiel M, Hendy GN, Hodsmann AB. Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: association with serum-induced cell proliferation. *Bone* 2000;26(3):221–5. [PubMed: 10709993]
40. Savard M, Barbaz D, Belanger S, Muller-Esterl W, Bkaily G, D'Orleans-Juste P, et al. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. *Journal of cellular physiology* 2008;216(1):234–44. [PubMed: 18264983]
41. Re M, Pampillo M, Savard M, Dubuc C, McArdle CA, Millar RP, et al. The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. *PLoS One* 2010;5(7):e11489. [PubMed: 20628612]
42. Theoharides TC, Kempuraj D, Marchand J, Tzianoumis L, Vasiadi M, Katsarou-Katsari A, et al. Urticaria pigmentosa associated with acute stress and lesional skin mast-cell expression of CRF-R1. *Clinical and experimental dermatology* 2009;34(5):e163–6. [PubMed: 19094125]
43. Yuan PQ, Wu SV, Elliott J, Anton PA, Chatzaki E, Million M, et al. Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis. *Peptides* 2012;38(1):62–9. [PubMed: 22948128]
44. Li Y, Song Z, Kerr KA, Moeser AJ. Chronic social stress in pigs impairs intestinal barrier and nutrient transporter function, and alters neuro-immune mediator and receptor expression. *PLoS One* 2017;12(2):e0171617. [PubMed: 28170426]
45. Smith F, Clark JE, Overman BL, Tozel CC, Huang JH, Rivier JE, et al. Early weaning stress impairs development of mucosal barrier function in the porcine intestine. *Am J Physiol Gastrointest Liver Physiol* 2010;298(3):G352–63. [PubMed: 19926814]

**Key messages**


- Loss of CRF<sub>2</sub> function induces exacerbated MC degranulation, IgE-mediated anaphylaxis and psychological stress-induced intestinal barrier dysfunction.
- MC-specific CRF<sub>2</sub> suppresses degranulation induced by diverse MC stimuli via negative regulation of SOCE.
- Further characterization of the mechanisms by which CRF<sub>2</sub> negatively modulates MC activation could lead to novel therapeutic approaches for stress-related immunological disorders associated with MC hyperactivity.



**FIG 1. CRF<sub>2</sub> deficiency exacerbates passive systemic anaphylaxis and intestinal permeability.** Wild type (CRF<sub>2</sub><sup>+/+</sup>) and CRF<sub>2</sub><sup>-/-</sup> female mice (6–8 weeks of age) were sensitized systemically overnight with IgE and challenged with either PBS vehicle (Control) or anti-IgE DNP to induce passive systemic anaphylaxis (PSA). **A**: Serum histamine levels were measured at 30 min post-vehicle or DNP challenge. **B**: rectal temperature was recorded at 0 and 30 min and the change in body temperature was calculated and presented as °C. **C**: Cardiac blood volume was measured at 0, 30 and 120 min post DNP challenge. **D**, **E**: 120 min post-DNP challenge, *ex vivo* colonic permeability was measured on Ussing chambers as FD4 flux rate (D) and TER (E). **F-H**: Tissues from WT and CRF<sub>2</sub><sup>-/-</sup> mice were fixed and stained with Toluidine blue and mast cell counts were performed and presented as mast cells/hpf. **G**: blood basophils were counted in blood smears and expressed at the % of basophils/100 WBCs. Data are means ± SEM from a representative experiment with n=6 animals per group. Experiments were repeated in n=6 (serum histamine, body temperature) or 2 (cardiac volume, mast cell and basophil counts) independent replicates. #,\* symbols differ by p<0.05 using a 1-Way ANOVA (A, D); Different asterisks indicate significance determine by unpaired two-tailed t-test (B, C, E),\*p<0.05, \*\*p<0.01.




**FIG 2. Localization of CRF1 and CRF2 in BMMCs and peritoneal mast cells.** CRF1 (Cy3 Red) and CRF2 (FITC Green) nuclei (DAPI blue). z-Stack overlay images show a single plane cross section through horizontal plane (XY), sagittal plane (YZ), and coronal plane (XZ). **Panels A-C** murine BMMCs. **Panels D-F** PMCs. White arrow indicates the nuclear staining pattern of CRF<sub>2</sub> (Panel C).



**FIG 3. Genetic deficiency and overexpression of CRF<sub>2</sub> induces divergent effects on stimuli induced MC degranulation. A:**


β-hex % release from IgE-sensitized WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs stimulated with DNP (32 ng/mL). **B, C:** β-hex release from WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs stimulated with A23187 (**B**) and c48/80 (**C**). **D:** Transmission electron microscopy analysis of WT and CRF<sub>2</sub><sup>-/-</sup> BMMCs stimulated with IgE/DNP. **E,F:** β-hex release from RBL-2H3 MCs transfected with CRF<sub>2</sub>-overexpressing plasmid or eGFP control or CRF<sub>2</sub>-siRNA. Data are means ± SEM from a representative experiment with n=3 (bone marrow donors) per group. Experiments were repeated in n=6 (A-C) or 2 (E-F) independent replicates. \*Significance between groups was determined by an unpaired two-tailed t-test, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001



**FIG 4. CRF<sub>2</sub> selective antagonism enhances mast cell degranulation in rodent and human mast cells.**

β-hex % release from RBL-2H3 mast cells (A) and human LAD2 cells (B) following pre-treatment with the CRF<sub>2</sub> antagonist drug Astressin 2B (A2B) at indicated concentrations.


\*\*p<0.01 1-Way ANOVA (n=6 replicates/treatment). Experiments repeated in n=3 independent experiments.



**FIG 5. CRF<sub>2</sub><sup>-/-</sup> BMMCs exhibit exacerbated Ca<sup>2+</sup> mobilization responses to diverse mast cell stimuli.**


Murine BMMCs from female mice were loaded with Fluo 4 Ca<sup>2+</sup> indicator and stimulated with indicated MC degranulation stimuli as described in the Material and Methods Section. Intracellular Ca<sup>2+</sup> mobilization (presented as F480/F540 or as representative traces) in response to indicated concentrations of IgE/DNP (A,E), A23187 (B,F) and c48/80 (C,G) and Carbachol (D,H). Data shown are the means  $\pm$  SE and are representative of 3 independent experiments performed in triplicate. Data were analyzed using a 1-way ANOVA \*P < 0.05, \*\*P < 0.001, \*\*\*P < 0.0001.






**FIG 6.  $\text{CRF}_2^{-/-}$  BMMCs exhibit heightened intracellular  $\text{Ca}^{2+}$  store release and expression of SOCE channels.**

BMMCs derived from WT and  $\text{CRF}_2^{-/-}$  mice were loaded with Fluo 4, and intracellular  $\text{Ca}^{2+}$  levels were measured following stimulation with IgE/DNP. **A,B:** Representative intracellular  $\text{Ca}^{2+}$  traces for experiments conducted under  $\text{Ca}^{2+}$ -replete (A) or  $\text{Ca}^{2+}$ -free (1 mM EDTA; B) conditions. **C:** Mean peak change in fluorescence following IgE/DNP stimulus presented as  $\Delta$  peak fluorescence. **D-I:** Representative Western blots and densitometry analysis for STIM1 (D, G), TRPC1 (E, H), and Orai (F, I) in WT and  $\text{CRF}_2^{-/-}$  BMMCs. \*Significance between groups was determined by an unpaired two-tailed t-test (C, G-I), \* $p < 0.05$ , \*\* $p < 0.01$ .



**FIG 7. CRF<sub>2</sub><sup>-/-</sup> mice exhibit heightened serum histamine levels and intestinal permeability following acute restraint stress.**

Wild type and CRF<sub>2</sub><sup>-/-</sup> mice female mice (8–10 weeks of age) underwent 1 h of restraint stress or housed under normal cage conditions (Control) as described in Materials and Methods. Serum histamine (A) and colonic permeability (B) was measured by ELISA following 1 h of restraint stress. Data are means ± SEM (n=8 mice/group). Data were analyzed using a 2-way ANOVA, \*p<0.05, \*\*p<0.01, #P=0.07.



**FIG 8. CRF<sub>2</sub> expressed on mast cells is a critical modulator of stress-induced intestinal permeability.**

Mast cell deficient *Kit<sup>W-sh/W-sh</sup>* mice were engrafted with BMMCs derived from WT or *CRF<sub>2</sub><sup>-/-</sup>* mice. Twelve weeks post-engraftment, mice were exposed to restraint stress (RS) for 3 hours. FD4 flux rate (A) and TER (B) measured from colon mounted on Ussing chambers from WT and *CRF<sub>2</sub><sup>-/-</sup>* BMMC-engrafted *Kit<sup>W-sh/W-sh</sup>* mice. C: MC numbers, determined with Toluidine blue staining in intestinal mesenteric windows from WT and *CRF<sub>2</sub><sup>-/-</sup>* engrafted *Kit<sup>W-sh/W-sh</sup>* mice. Data are means ± SEM (n=8 mice/group).

Experiments were repeated in two independent studies. Data were analyzed using a 2-way ANOVA, \*p<0.05.